Internal Reference Number: FOI_6990
Date Request Received: 25/01/2023 00:00:00
Date Request Replied To: 09/03/2023 00:00:00
This response was sent via: By Email
Request Summary: High-cost drugs in Ophthalmology
Request Category: Private Individuals
| Question Number 1: For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition: Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab - Lucentis Ranibizumab - Ongavia | |
| Answer To Question 1: Aflibercept (Eylea) 752 Bevacizumab (Avastin) 6 Brolucizumab 0 Dexamethasone (Ozurdex) 7 Faricimab (Vabysmo) 93 Ranibizumab (Lucentis) 11 Ranibizumab (Ongavia) 0 | |
| Question Number 2: For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab - Lucentis Ranibizumab - Ongavia | |
| Answer To Question 2: Aflibercept (Eylea) 62 Bevacizumab (Avastin) <5 Brolucizumab 0 Dexamethasone (Ozurdex) <5 Faricimab (Vabysmo) 9 Ranibizumab (Lucentis) 0 Ranibizumab (Ongavia) 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
